Avoiding misclassification of thrombotic primary antiphospholipid syndrome as systemic lupus erythematosus (SLE): What are the best-performing SLE classification criteria?

Abstract

Background

Systemic lupus erythematosus (SLE) and Primary Antiphospholipid Syndrome (PAPS) overlap clinical and immunological features. Therefore, misclassification of PAPS patients as SLE is a concern. The ACR/EULAR 2019 SLE classification has never been studied in PAPS.

Objective

To verify if the ACR/EULAR 2019 SLE classification can correctly classify a PAPS patient as not having SLE and compare its performance with the SLICC 2012 SLE classification. Methods: One-hundred thrombotic PAPS patients who fulfilled the Sidney criteria were consecutively screened and those who attended the inclusion criteria were submitted to ACR/EULAR 2019 and SLICC 2012 classifications.

Results

Sixty-seven PAPS patients were included in this study. The majority was female (89.6%) with median age at study inclusion of 45 years (35–53) and median PAPS disease duration of 13 years (8–19). PAPS correct classification was observed more often with ACR/EULAR 2019 than SLICC 2021 criteria (94.0% vs. 64.2%; p < 0.001). The 4 misclassified patients in ACR/EULAR 2019 were also misclassified in SLICC 2012. The comparison of misclassified patients to those correctly not classified as SLE resulted, for both criteria, in higher frequencies of hematological domain [ACR/EULAR 2019 (100% vs. 28.6%, p = 0.010) and SLICC 2012 (95.8% vs. 11.6%, p < 0.001)]. Further analysis of hematological manifestations revealed that for the ACR/EULAR 2019 leukopenia (100% vs. 22.2%, p = 0.004) and for the SLICC 2012 leukopenia/lymphopenia (91.7% vs. 7%, p < 0.001) were more frequent in misclassified group. Proteinuria (20.8% vs. 0%, p = 0.004) and low complement (45.8% vs. 20.9%, p = 0.033) were also more often observed in the incorrectly SLICC 2012 classified patients.

Conclusion

ACR/EULAR 2019 had high accuracy for distinguishing PAPS from SLE, whereas the SLICC 2012 incorrectly classified more than one third of the PAPS patients as having SLE.

Keywords

Systemic lupus erythematosus primary antiphospholipid syndrome ACR/EULAR 2019 criteria and SLICC 2012 criteria

Get full access to this article

View all access options for this article.

References

Miyakis

Lockshin

Atsumi

, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.

Cervera

Lessons from the “euro-phospholipid” project. Autoimmun Rev 2008; 7: 174–178.

Hochberg

MC.

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997; 40: 1725.

Petri

Orbai

Alarcón

, et al. Derivation and validation of the systemic lupus international collaborating. Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–2686.

Aringer

Costenbader

Daikh

, et al. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Arthritis Rheumatol 2019; 71: 1400–1412.

Paule

Morel

Le Guern

, et al. Classification of primary antiphospholipid syndrome as systemic lupus erythematosus: analysis of a cohort of 214 patients. Autoimmun Rev 2018; 17: 866–872.

Devreese

de Groot

de Laat

, et al. Guidance from the scientific and standardization committee for lupus anticoagulant/antiphospholipid antibodies of the international society on thrombosis and haemostasis—update of the guidelines for lupus anticoagulant detection and interpretation. J Thromb Haemost 2020; 18: 2828–2839.

Ginzler

Dooley

Aranow

, et al. Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis. N Engl J Med 2005; 353: 2219–2228.

Lofvenberg

Wahlin

Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988; 41: 375–381.

10.

Adamichou

Nikolopoulos

Genitsaridi

, et al. In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. Ann Rheum Dis 2020; 79: 232–241.

11.

Noureldine

MHA

Khamashta

MA, M

Merashli

Sabbouh

Hughes

GRV

Uthman

Musculoskeletal manifestations of the antiphospholipid syndrome. Lupus 2016; 25: 451–462.

12.

Assan

Seror

Mariette

Nocturne

New 2019 SLE EULAR/ACR classification criteria are valuable for distinguishing patients with SLE from patients with pSS. Ann Rheum Dis. Epub ahead of print 9 September 2019. DOI: 10.1136/annrheumdis-2019-216222.

13.

Ehrenstein

Swana

Keeling

Asherson

Hughes

Isenberg

DA.

Anti-DNA antibodies in the primary anriphospholipid syndrome (PAPS). Br J Rheumatol 1993; 32: 362–365.

14.

Arbuckle

McClain

Rubertone

, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526–1533.

15.

Carneiro

Ruiz

Freitas

Isenberg

A comparison of three classification criteria sets for systemic lupus erythematosus – a study looking at links to outcome and mortality. Arthritis Care Res (Hoboken) 2020; 72: 1611–1614.

16.

Gómez-Puerta

Martín

Amigo

M-C

, et al. Long-term follow-up in 128 patients with primary antiphospholipid syndrome: do they develop lupus? Medicine (Baltimore) 2005; 84: 225–230.